GNW-Adhoc: Novotech team visits BIO Europe to explain the benefits of expanding global operations

^SINGAPORE, March 08, 2023 (GLOBE NEWSWIRE) — Novotech, the leading, im

Asia Pacific-based biotech contract research organization (CRO),

will be at BIO Europe (March 20-22, 2023) with biotech companies in the

clinical stage coincide and the benefits of recent

Presenting Novotech’s expansion in Europe.

At JPMorgan earlier this year, Novotech announced the acquisition of EastHORN, a

European CRO with clinical, medical and regulatory expertise

several strategically important locations on the continent.

EastHORN, which retains its brand, is now a Novotech company and will

integrated into Novotech’s systems and processes so that customers benefit from the

Working with just one CRO worldwide.

The acquisition is part of Novotech’s global expansion program. EastHORN

was founded in 2004 and has over 250 employees.

The acquisition of EastHORN means customers in the biotechnology industry

throughout Europe and the USA access to the unique and unparalleled offer

Have early to late stage CRO services from Novotech. The

However, the focus is on the Asia-Pacific region, where the

Company has a good reputation for expedited implementation

high-quality clinical studies.

dr John Moller, CEO of Novotech said:

?This acquisition is a strategic step to further our CRO activities

to expand and our customers from the biotechnology industry within the countries

of Asia-Pacific, North America and Europe in relation to their

to support global drug development programs with expertise.

We have worked together for many years and share a clinical culture

Excellence in biotechnological drug development.

Customers can now rely on our exceptional European infrastructure,

our local knowledge, our relationships with trial sites and our access to

different patient groups.”

Novotech has decades of experience in biotechnology

drug development, has established relationships with trial sites and

investigators, access to large patient populations and follow-up

Project management approach that focuses on problem solving, ownership and

flexibility focused. Consistent investments in progressive

Training and technology provide exceptional full-service CRO

Solution in the field of biotechnology.

Novotech has recently been recognized with major CRO awards including

Frost & Sullivan’s “Asia-Pacific Biotech CRO of the Year” award,

ranking as one of the top 10 CROs among the world’s leading CROs,

the nomination as a finalist at the prestigious Scrip Awards and the

Presentation of the Gene & Cell Therapy Excellence Award.

In Asia Pacific, Novotech has more than 50 Leading Site Partnership

Agreements with major medical research institutions

closed, which offer the sponsors exclusive advantages.

About Novotech Novotech-CRO.com (https://novotech-cro.com/)

Novotech is the leading CRO in Asia Pacific with worldwide

Implementation options. Novotech is a clinical contract research organization

with laboratories, Phase I facilities, consulting services for the

Drug development and FDA approvals expertise and has experience

with over 5,000 clinical projects, including clinical trials of the

Phases I to IV and bioequivalence studies. Novotech is able to customers from

the biotechnology industry in conducting clinical trials in Asia

Pacific Rim, USA and Europe. Novotech has

more than 3,000 employees worldwide and 33 offices in the USA, Europe and the

Asia Pacific.

Visit https://novotech-cro.com/contact for more information

°

ttn-28